Teliora (triamcinolone acetonide/pentoxifylline)

For the management of intermittent claudication associated with peripheral vascular disease (i.e., chronic occlusive arterial disease), the usual adult dosage of pentoxifylline as extended-release tablets is 400 mg 3 times daily. If adverse GI and/or CNS effects develop, dosage should be reduced to 400 mg twice daily; if adverse effects persist at this lower dosage, the manufacturer recommends that the drug be discontinued. Although symptomatic relief may occur in some patients within 2-4 weeks following initiation of pentoxifylline therapy, the manufacturer recommends that treatment with the drug be continued for at least 8 weeks to determine efficacy. Although longer term therapy may be necessary, the manufacturer states that efficacy of the drug to date has been established in well-controlled studies up to 6-months' duration.

Dermatologic preparations of triamcinolone acetonide are applied sparingly in thin films and are rubbed gently into the affected area 2-4 times daily. The 0.5% cream and 0.5% ointment should be used only in the treatment of dermatoses which are refractory to treatment with lower concentrations. The 0.1 and 0.5% creams are applied 2-3 times daily according to severity of the condition. When the aerosol is applied, an area about the size of the patient's hand is sprayed for about 2 seconds from a distance of about 7.5-15 cm 3 or 4 times daily. Occlusive dressings may be used for severe or resistant dermatoses.

For use in the mouth, a small amount (about 0.6 cm) of the 0.1% paste is pressed to the lesion without rubbing until a thin film develops; a larger amount may be required to cover some lesions. The paste is applied at bedtime and, if necessary, 2 or 3 times daily, preferably after meals. If substantial regeneration or repair of the oral tissues does not occur after 7 days of treatment, further investigation of the etiology of the oral lesions should be undertaken.

Pentoxifylline is administered orally, preferably with meals.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

• Adrenocortical insufficiency
• Telangiectasia

There is no enhanced messaging for this drug.

Less Frequent

• Folliculitis
• Purpura
• Skin and skin structure infection
• Skin atrophy

Rare or Very Rare

• Adrenocortical insufficiency
• Bullous dermatitis
• Cataracts
• Central serous chorioretinopathy
• Glaucoma
• Growth failure
• Hypothalamic-pituitary insufficiency
• Intracranial hypertension
• Ocular hypertension
• Skin hypopigmentation
• Skin striae
• Skin ulcer
• Urticaria

More Frequent

• Erythema
• Stinging of skin

Less Frequent

• Acute pain at drug application site
• Blurred vision
• Headache disorder
• Paresthesia
• Pruritus of skin
• Skin rash
• Telangiectasia
• Treatment site sequelae

Rare or Very Rare

• Acneiform eruption
• Alopecia
• Blistering skin
• Contact dermatitis
• Dry skin
• Dyschromia
• Glycosuria
• Hirsutism
• Hypercortisolism
• Hyperesthesia
• Hyperglycemia
• Miliaria
• Perioral dermatitis
• Skin irritation

No enhanced messaging available.

No enhanced messaging available.

Reproduction studies in rats and rabbits using oral pentoxifylline dosages up to about 25 and 10 times the maximum human dosage, respectively, have not revealed evidence of fetal malformation; however, an increased incidence of fetal resorption was observed in pregnant rats receiving oral pentoxifylline dosages 25 times the maximum human dosage. There are no adequate and controlled studies to date using pentoxifylline in pregnant women, and the drug should be used during pregnancy only when clearly needed.

Pentoxifylline and its metabolites are distributed into milk. Because of the tumorigenic potential exhibited by pentoxifylline in rats, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.

No enhanced messaging available.